BioWorld

April 4, 2008

Denosumab Builds Bone Density, but Infection Concerns Emerge

Amgen Inc.'s experimental osteoporosis drug, denosumab, met all bone mineral density (BMD) endpoints for all skeletal sites in a two-year, 332-patient Phase III study. (BioWorld Today) Read More

Dendreon Will Fund Provenge, Other Trials with $47M Offering

TGF-Beta Gets Breast Tumors Primed for Lung Metastasis

NewCo News: SynDevRx Off to a Fast Start, with Funding and Trials Ahead

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...